Exagen: Tina Nova

Exagen has elected Tina Nova as executive chair of its board of directors. Nova succeeds Brian Birk, who served as chair of the board since 2018 and will remain as a board member.

Nova currently serves as president of Veracyte's CLIA business. She was previously president and CEO of Decipher Biosciences until March 2021, when Veracyte acquired Decipher. Nova has also been CEO of Molecular Stethoscope and senior VP and general manager of oncology at Illumina. She was the cofounder, president, and CEO of Genoptix, which was acquired by Novartis in 2011. Nova also serves on the board of Azenta and has been a board member with Veracyte and Arena Pharmaceuticals. She holds a PhD in biochemistry from the University of California, Riverside and a BS in biological sciences from UC Irvine.